Mike Firth

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

Andreas Kindmark, A Jawaid, Chris Harbron et al. · The Pharmacogenomics Journal · 2007 · 365 citations

Genetic Epidemiology, Immunology, Pathology +17

In vivo CRISPR editing with no detectable genome-wide off-target mutations

Pınar Akçakaya, Maggie Bobbin, Jimmy A. Guo et al. · Nature · 2018 · 315 citations · Full text

Vivo Crispr, Natural Sciences, Genetics +8

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Nicola J. Curtis, Lorraine Mooney, Lorna Hopcroft et al. · Oncotarget · 2017 · 149 citations · Full text

Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing

Sandra Wimberger, Nina Akrap, Mike Firth et al. · Nature Communications · 2023 · 107 citations · Full text

Engineered Cas9 extracellular vesicles as a novel gene editing tool

Xabier Osteikoetxea, Andreia Silva, Elisa Lázaro‐Ibáñez et al. · Journal of Extracellular Vesicles · 2022 · 105 citations · Full text